App-Quantinova.ai

Truncated HER2 Receptor in Circulating Tumor Cells (CTCs) of Early and Metastatic Breast Cancer Patients

Kallergi G - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Long Term Independent Prognostic Impact of Circulating Tumor Cells Detected before Neoadjuvant Chemotherapy in Non-Metastatic Breast Cancer: 70 Months Analysis of the REMAGUS02 Study

Bidard F-C - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Association between Circulating Tumor Cells and Bone Turnover Markers in Patients with Breast Cancer and Bone Metastases on Treatment with Bisphosphonates (ZOMAR Study)

Manso L - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

Alkaline phosphatase

Different Numbers and Prognostic Significance of Circulating Tumour Cells in Patients with Metastatic Breast Cancer According to Immunohistochemical Subtypes.

Peeters DJ - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Tumor Cell Emboli in the Lung and Transcriptional Profiles of Circulating Tumor Cells Derived from Different Vascular Compartments in Patients with Metastatic Breast Cancer.

Peeters DJ - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Immunocytochemistry Staining for Estrogen and Progesterone Receptor in Circulating Tumor Cells: Concordance between Primary and Metastatic Tumors.

Bischoff FZ - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Circulating Tumor Cells and Epithelial Mesenchymal Transition in Primary Breast Cancer Patients.

Mego M - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prognostic Value of Circulating Tumor Cells Count at Progressive Disease after First Line Chemotherapy Metastatic Breast Patients in a Large Prospective Multicenter Trial Including Serum Tumor Markers (IC 2006-04 Study)

Pierga J-Y - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

circulating Tumor Cells in Breast Cancer Exhibit Dynamic Changes in Epithelial and Mesenchymal Cell Composition

Yu M - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Identification of Cancer Stem Cells (CD44+CD24-/lo) in Bone Marrow as a Prognostic Factor in Early Breast Cancer Patients

Giordano A - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Association between Circulating Tumor Cells and Molecular Breast Cancer Subtypes

Gang N - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Evaluation of Circulating Tumor Cell as a Marker of Prognosis and Efficacy in a Randomized Phase III Study in HER2 Negative Metastatic Breast Cancer Patients Treated with Capecitabine and Docetaxel: JO21095 Study

Masuda N - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Capecitabine

First-Line Chemotherapy with Pegylated Liposomal Doxorubicin Versus Capecitabine in Elderly Patients with Metastatic Breast Cancer: Results of the Phase III OMEGA Study of the Dutch Breast Cancer Trialists- Group (BOOG)

Smorenburg CH - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Doxorubicin Hydrochloride

Detection and Characterization of Circulating and Disseminated Tumour Cells in Blood and Bone Marrow of Breast Cancer Patients by Two Different Biochemical Methods

Andergassen U - San Antonio Breast Cancer Symposium (SABCS) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Impact of GvHD-prophylaxis regimen on incidence and severity of gastrointestinal toxicities and acute GvHD after allogeneic HSCT

J. Niestadtkoetter - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Mucositis

Cyclosporine A

Circulating tumor cells (CTCs) and Autologous hematopoietic stem cell transplantation in triple negative metastatic breast cancer

J. M. Reuben - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Filgrastim

An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

Peter M Voorhees - American Society of Hematology (ASH) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma

Yuji Mishima - American Society of Hematology (ASH) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Rapid and Sensitive Detection of Circulating Tumor Cells with Nuclease-Activated Oligonucleotide Probes

David D. Dickey - American Society of Gene & Cell Therapy (ASGCT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Evaluation of Computed Tomographic Colonography in Routine Practice in a Tertiary Referral Center

Mark Borgaonkar - Digestive Disease Week (DDW) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Abdominal aortic aneurysm

N/A

Filters

1671 Abstracts